Qilian International Hold...

5.41
-0.20 (-3.57%)
At close: Aug 09, 2024, 8:00 PM

Company Description

Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China.

The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions.

It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications.

In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application.

Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth.

The company was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Qilian International Holding Group Limited
Qilian International Holding Group Limited logo
Country CN
IPO Date Jan 12, 2021
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 298
CEO Chen Xin

Contact Details

Address:
Jiuquan Eco & Tech Dev Zn
Jiuquan,
CN
Website https://www.qlsyy.net

Stock Details

Ticker Symbol QLI
Exchange NASDAQ
Fiscal Year October - September
Reporting Currency USD
CIK Code 0001779578
CUSIP Number G7307E107
ISIN Number KYG7307E1070
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Chen Xin Chief Executive Officer
Yaxuan Zhai Chief Financial Officer
Zhanchang Xin Chairman of the Board, President, Chief Operating Officer & Chief Scientific Officer

Latest SEC Filings

Date Type Title
Apr 03, 2025 20-F/A [Amend] Filing
Mar 28, 2025 6-K Filing
Mar 19, 2025 6-K Filing
Mar 07, 2025 F-3 Filing
Feb 28, 2025 6-K Filing
Feb 06, 2025 20-F/A [Amend] Filing
Jan 27, 2025 20-F Filing
Jan 07, 2025 6-K Filing
Jan 06, 2025 SCHEDULE 13D Filing
Dec 03, 2024 SC 13D Filing